Lumos Diagnostics Holdings Ltd (ASX: LDX) Share Price and News

Ms Le Grice has over two decades of executive experience spanning health technology commercialisation, venture capital, capital raising and industry advocacy. Formerly an Investment Director at leading healthcare VC firm, BioScience Managers, Ms Le Grice has experience across buy side and sell side transactions within the health and medical technology sectors. Ms Le Grice currently has served as a Member of the National Health & Medical Research Council (NHMRC) since 2021, and chairs the inaugural NHMRC-MRFF Industry, Philanthropy and Commercialisation Committee, providing strategic advice on industry and philanthropic involvement in health and medical research, development and commercialisation. She also Chair the Disclosure Committee, Member of the Risk Committee.

Ms Robson has more than 25 years of experience in management, finance and investment. Ms Robson currently serves as a Non-Executive Director for ASX listed Equity Trustees (EQT Holdings Limited), where she is the chair of the Risk Committee and member of the Audit and Remuneration, Human Resources and Nominations Committees. Ms Robson currently chairs the Board of fully owned subsidiary Equity Trustees Superannuation Limited. Ms Robsons other Board appointments include Newcastle Greater Mutual Group, where she chairs the Audit Committee and the Australian Business Growth Fund, the private equity fund where she is the chair of the Audit and Risk Committee. She also chair of the Risk Committee.

Mr Mehren served as President and Chief Executive Officer as well as a Director of Accelerate Diagnostics from 2012 to 2020. Prior to this, Mr Mehren was the Head of Global Business for Ventana Medical Systems and Roche Tissue Diagnostics managing its four business units. He also held various global leadership positions with Ventana including Senior Vice President of Emerging Businesses and Chief Financial Officer. Mr Mehren was also Managing Director, Partner and Head of P&M Corporate Finances life sciences practice.

Mr Lanyon has more than 30 years of experience in strategy, sales and operations with a track record in the global commercialization of technology rich healthcare products. Mr Lanyon currently serves as Executive Director and co-founder of Planet Innovation. Previously, Mr Lanyon held various board roles for unlisted businesses such as Visus Therapeutics Inc. and Paragon Funds Management as well as international executive roles with Leica Microsystems, part of Danaher Corporation, and ASX listed Vision Systems Ltd. He is a member of the Risk Committee.

Mr Ward has more than 30 years of biotech and medical technology experience at global healthcare companies including Roche, GE, Siemens, Bayer, Chiron and Hologic. During his career, Mr Ward has held executive positions where he developed and implemented novel business strategies and introduced transformational products to the practice of medicine. Prior to joining Lumos, he served as Vice President, Strategy and Business Development at Hologic where he led a global team responsible for fostering innovation in womens healthcare to improve clinical results. Mr Ward also served as the CEO of Personal Genome Diagnostics (PGDx). He brings experience across all company functions, including Commercial Leadership, R&D, Operations, Quality, Regulatory, Service, and Support.

-

-

-

-

-

-

-

-

-

-

-